Vidac Pharma Receives Renewed “Buy” Rating from Sphene Capital Following German Authorization for New Phase 2 AK Trial
Vidac wins renewed “Buy” rating as Phase 2 AK trial gets green light in Germany -analysts see major upside ahead. Vidac Pharma Holding Plc. (XSTU:T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ) LONDON, UNITED KINGDOM, November 21, 2025 /EINPresswire.com/ …